Tag: CheckMate-238

NICE rejects Opdivo for preventing melanoma recurrence

by Selina McKee | Sep 11, 2018 | News | 0

NHS funding for use of Bristol-Myers Squibb’s Opdivo as an adjuvant treatment for resected stage III and IV melanoma is being blocked by the National Institute for Health and Care Excellence.

BMS’ Opdivo cuts risk of melanoma recurrence

by Selina McKee | Jun 5, 2018 | News | 0

Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence, may significantly cut the risk of patients’ cancer returning.